Premium
ANALYSIS OF IMMUNE RELATED ADVERSE EVENTS IN NSCLC PATIENTS RECEIVING DURVALUMAB AFTER CHEMORADIOTHERAPY IN THE REAL‐WORLD CLINICAL SETTING
Publication year - 2019
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13699_139
Subject(s) - durvalumab , medicine , adverse effect , chemoradiotherapy , oncology , intensive care medicine , nivolumab , immunotherapy , cancer , overall survival
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom